ABILITY Diabetes Global enrolls thousandth patient: A Cardinal Milestone Achieved
PR91573
TAMPA, Fla., Sept. 9, 2021 /PRNewswire=KYODO JBN/ --
ABILITY Diabetes Global
[https://www.conceptmedical.com/clinical-program/ability-diabetes-global/]
(Randomized Comparison of Abluminus DES+ Sirolimus-Eluting Stents versus
Everolimus-Eluting Stents in Coronary Artery Disease Patients with Diabetes
Mellitus Global) started off with the index patient enrolment on 11th June 2020
in Italy (at the peak of the 1st wave of COVID-19 pandemic) by P.I. Prof.
Antonio Colombo and the pace of enrolment since then has been steady and
consistent, with a thousand patients being enrolled in just over a year.
Despite COVID-19 ravaging world over, the pace of enrolment is remarkable
considering the fact that the healthcare facilities are occupied in caring for
patients hospitalized with COVID-19. Although COVID-19 crisis still looms over
us, Cardiovascular Disease (CVD) remains the number one killer and Diabetes
continues to be the key comorbidity and contributor to Coronary Artery Disease
(CAD).
ABILITY Diabetes Global
[https://www.conceptmedical.com/clinical-program/ability-diabetes-global/] is
the world's largest Randomized Controlled Trial (RCT) for CAD patients with
diabetes as a comorbidity. This RCT measures the safety and efficacy of the
Abluminus DES+ [https://www.conceptmedical.com/product/abluminus-des/] which is
specially crafted with the patented Envisolution Technology and has proven to
be effective in managing the proliferative CAD lesions seen in DM.
With the promising pace of enrolment so far, Concept Medical
[https://www.conceptmedical.com/] eagerly looks forward to the completion and
results of ABILITY Diabetes Global targeting more than 3000 diabetic patients,
across 100 centres, spanning more than 25 countries against the XIENCE EES
family (Abbott Cardiovascular).
Concept Medical is delighted to be a part of this achievement which is a
direct result of endless support, guidance, and experience of Prof. Roxana
Mehran (Chairperson), Prof. Marie-Claude Morice (Medical Director), Prof.
Alexandre Abizaid, Prof. Antonio Colombo & Prof. Shigeru Saito (Principal
Investigators), and the entire steering committee. Contributing to this
achievement are the sites who showed encouragement in participation with the
top enrollers so far being - Instituto Dante Pazzanese, Sao Paulo, Brazil (Dr.
Chamié), National Heart Foundation Hospital and Research Institute, Dhaka,
Bangladesh (Prof. Malik), Herzzentrum Segeberger Kliniken, Bad Segberg, Germany
(Dr. Allali) and many more. It is the dedication and commitment of all the
sites, the site investigator, and technicians for accomplishing this. The
credit also extends to Cardiovascular European Research Center (CERC), Mount
Sinai and ICAHN School of Medicine for their valuable contribution and constant
coordination every day which is of utmost importance.
At this point, when the trial is proceeding with excellent engagement from
its investigators, and coordinators. Prof. Mehran expresses her enthusiasm, "I
am encouraged by the progress we are making on this largest trial in PCI and
Diabetes and incredibly enthusiastic about the future of what we can offer to
these complex patients with progress in innovation in PCI."
Prof. Marie-Claude Morice, CEO of CERC expresses her thoughts, "The CERC
team is pleased to work hand in hand with the Mount Sinai and the Concept
Medical team. We are extremely proud to achieve this important milestone. This
study is significant for Diabetic patients with coronary disease who continue
to be treated sub optimally with current devices. The 'non-COVID' patients
should not be ignored during pandemic period. Thanks to the highly motivated
investigators and study coordinators, we were able to obtain consent from the
respective ethics committees which enabled us to enroll 1000 patients at such a
fast pace."
For a company with the vision of Advancing Innovation, the 1000 patient
enrolment is a significant milestone towards a possible breakthrough in the
medical device industry. Concept Medical [https://www.conceptmedical.com/]
looks to progress rapidly and add one more milestone to its credit.
About Concept Medical Inc (CMI):
CMI is headquartered in Tampa, Florida and has operational offices in The
Netherlands, Singapore and Brazil and manufacturing units in India. CMI
specializes in developing drug-delivery systems and has unique and patented
technology platforms that can be deployed to deliver any drug / pharmaceutical
agent across the luminal surfaces of blood vessels.
Photo:
https://mma.prnewswire.com/media/1611910/Concept_Medical_NY_Times_Sqaure.jpg
Logo: https://mma.prnewswire.com/media/1244676/Concept_Medical_Logo.jpg
Source: concept Medical Inc.
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。